TransMedics(TMDX)2025-02-27 21:15Revenue Performance - Total revenue for Q4 2024 was 81.2 million in Q4 2023[5] - Full year 2024 total revenue reached 241.6 million in 2023[10] - TransMedics expects total revenue for 2025 to be between 552 million, representing 20% to 25% growth compared to 2024[14] Net Income - Net income for Q4 2024 was 0.19 per diluted share, compared to 35.5 million, or 25.0 million in 2023[13] Gross Margin and Operating Expenses - Gross margin for Q4 2024 was 59.2%, slightly up from 59.0% in Q4 2023[7] - Operating expenses for Q4 2024 were 45.3 million in Q4 2023, driven by R&D investments[8] Market Performance - The company completed 3,715 U.S. OCS cases in 2024, a 58% increase from 2,347 cases in 2023[6] - OCS market share for 2024 was 20.9%, up from 13.8% in 2023[6] Cash and Assets - Cash as of December 31, 2024, was 330.1 million as of September 30, 2024[13] - Total assets increased to 706,047 million in 2023, representing a growth of approximately 13.9%[23] Stockholders' Equity - Total stockholders' equity rose significantly to 137,202 million in 2023, marking an increase of about 66.7%[23] Current Assets and Liabilities - Current assets decreased slightly to 510,654 million in 2023, a decline of approximately 2.5%[23] - Total current liabilities rose to 54,934 million in 2023, an increase of approximately 9.0%[23] Accounts Receivable and Payable - Accounts receivable increased to 63,576 million in 2023, reflecting a growth of about 53.6%[23] - Accounts payable decreased to 12,717 million in 2023, a decline of approximately 19.1%[23] Debt and Liabilities - Convertible senior notes remained relatively stable at 447,140 million in 2023, showing a minimal change[23] - Long-term debt increased slightly to 59,064 million in 2023, indicating a growth of about 0.5%[23] - Operating lease liabilities, net of current portion, decreased to 7,707 million in 2023, a reduction of about 19.0%[23] Inventory - Inventory increased to 44,235 million in 2023, reflecting a growth of approximately 5.2%[23]